Best Oncology Companies in Victoria, Australia
The 39 best Oncology companies in Victoria, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Radiopharm Theranostics.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Victoria
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Radiopharm Theranostics Manufacturer of radiopharmaceutical products for diagnostic test | $46M | 25 mo ago | Public | — | Paul Hopper Executive Chairman & Founder | WordPressMySQLPHP+21 | — | — |
| 2 | Immuron Developer of oral immunotherapy utilizing polyclonal antibody products | $37M | 73 mo ago | Public | 6 | Jerry Kanellos CEO | Cart FunctionalityWooCommerceWordPress+19 | 79 patents Hyperimmune bovine colostrum therapeutics for gastrointestinal and respiratory infectious diseases | 1 launch |
| 3 | Ena Respiratory Developer of antiviral host defense enhancers for respiratory infections. | $25M | 10 mo ago | Series B | 9 | Christophe Demaison Managing Director | — | 38 patents TLR2‑agonist lipid immunostimulants for respiratory infection and allergy therapy | — |
| 4 | Telix Pharma Developer of theranostic radiopharmaceuticals for imaging and treating cancer | $25M | 70 mo ago | Public | 234 | — | DrupalApple iCloud MailPHP+28 | — | 1 award |
| 5 | ChemGenex Pharmaceuticals Specialty company developing oncology drugs | $21M | 233 mo ago | Acquired | 6 | — | — | 15 patents Homoharringtonine-based therapies for kinase‑inhibitor‑resistant chronic myeloid leukemia | — |
| 6 | Chimeric Therapeutics Provider of CAR T cell therapies for solid tumors | $21M | 22 mo ago | Public | 19 | Paul Hopper Executive Chairman & Founder | WixSentryBootstrap+13 | — | 1 award |
| 7 | Noxopharm Developer of drugs for the treatment of cancer and septic shock | $18M | 29 mo ago | Public | 17 | — | ZURB FoundationMicrosoft ASP.NETAmazon ALB+12 | 65 patents Isoflavone-derived compounds for cancer immunotherapy and infection‑related inflammation treatment | — |
| 8 | Exopharm Developer of exosome-based therapeutics for targeted treatments | $12M | 64 mo ago | Public | 39 | — | — | 30 patents Exosome/microvesicle isolation methods and fluorescent labeling dyes for biomedical research | — |
| 9 | Cartherics Developer of cellular immunotherapy for cancer | $10M | 23 mo ago | Series B | — | Ian Nisbet Co-Founder and Chief Operating Officer | WordPressCart FunctionalityMySQL+18 | — | 1 award |
| 10 | Currus Biologics Developer of CAR-T cell therapies for solid tumors | $10M | 62 mo ago | Series A | 5 | Sam Cobb CEO | — | 16 patents Engineered anti-flag and bispecific polypeptide immunotherapies to rejuvenate exhausted immune cells | — |
| 11 | INOVIQ Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer | $6M | 10 mo ago | Public | 5 | Leearne Hinch CEO | Cart FunctionalityZURB FoundationMicrosoft ASP.NET+20 | 4 patents Extracellular vesicle therapeutics and polymer resin formulations for drug delivery | — |
| 12 | Adalta Developing next-generation antibody therapeutics for the treatment of fibrosis and cancer. | $3M | 28 mo ago | Public | 12 | — | WordPressPleskMySQL+22 | 18 patents Therapeutic biologics targeting CXCR4, RANKL, and malaria antigen binding polypeptides | 1 partnership |
| 13 | Prescient Therapeutics Targeted small molecule inhibitors of Ras and Akt pathway for the treatment of cancer | $3M | 72 mo ago | Public | 1 | Wayne Millen CEO | WordPressMySQLPHP+28 | 16 patents Patents concentrated in health & consumer products | — |
| 14 | Rhythm Biosciences Developer diagnostic tests for the detection of cancer | $3M | 26 mo ago | Public | — | David Atkins Chief Executive Officer | WordPressMySQLPHP+21 | — | 1 partnership |
| 15 | PredicTx Health Developer of a platform for personalized chemotherapy dosing using body analysis | $2M | 10 mo ago | Seed | — | Justin Yeung Co-Founder & CMO | — | — | — |
| 16 | Patrys Specialty company developing products for treatment of cancer | $2M | 48 mo ago | Public | 23 | James Campbell CEO and Managing Director | — | 90 patents Therapeutic antibodies targeting LM-1 antigen for cancer and metabolic applications | — |
Top 12 Oncology companies in Victoria
#1
Series B · Melbourne, Victoria · founded 2020 · 9 employees$25Mraised▾
{}
- Oct 2025Series B$22.4M
- Feb 2025Series B$5M
- Jun 2021Series B$25M
#2
Public · Notting Hill, Victoria · founded 1983 · 5 employees$6.1Mraised▾
Developer of a portfolio of diagnostic and exosome-based products for the diagnosis and treatment of cancer. The company has an hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes.
- Oct 2025Post IPO$6.1M
#3
Public · Carlton, Victoria · founded 2020 · 19 employees$20.8Mraised▾
Provider of CAR T cell therapies for solid tumors. The company offers its proprietary clinical-stage CLTX-CART technology that includes chlorotoxin (CLTX), which is a peptide obtained from scorpion toxin, which targets the CAR-T cell in solid tumors.
- Oct 2024Post IPO$3.4M
- Jun 2023Post IPO$10.1M
- Feb 2022Post IPO$7.4M
#4
Seed · Melbourne, Victoria · founded 2025$1.6Mraised▾
Developer of a platform for personalized chemotherapy dosing using body analysis. The platform analyzes CT scans to segment muscle, fat, bone, and tumor volume. This creates a detailed body composition profile for each patient. Machine learning models then predict the optimal chemotherapy dose before the first cycle.
- Oct 2025Seed$1.6M
#5
Series B · Notting Hill, Victoria · founded 2014$10.4Mraised▾
Developer of cellular immunotherapy for cancer. The company has developed their technology platform combined with stem cells and immunotherapy (gene-modified antigen-specific T cell and chimeric antigen receptor technology) which helps in genetic enhancement of cytotoxic killer T cells and provides dual cancer binding receptors. It is used to treat cancers like relapsed ovarian cancer and gastric cancers.
- Oct 2024Series B$10.4M
- Sep 2022Grant (prize money)$3.6M
#6
Public · Carlton, Victoria · founded 2021$45.8Mraised▾
Manufacturer of radiopharmaceutical products for diagnostic test
- Jul 2024Post IPO$45.8M
- Feb 2024Post IPO—
#7
Public · Melbourne, Victoria · founded 2015 · 17 employees$18.3Mraised▾
Developer of drugs for the treatment of cancer and septic shock. Its lead product Veyonda is to work with chemotherapy and radiotherapy against cancer. The other drugs include DARRT-1, LuPIN an enhancing radiotherapy program to treat metastatic Castrate Resistant Prostate Cancer (mCRPC), and CEP-1 chemotherapy enhancing program for the treatment of metastatic solid tumors (breast, prostate, lung, ovarian, and head & neck).
- Apr 2024Grant (prize money)$100K
- Jun 2022Grant (prize money)$1M
- Nov 2021Grant (prize money)$6.4M
- Mar 2018Post IPO$10.8M
#8
Public · Camberwell, Victoria · founded 2010 · 2 employees$30Kraised▾
Developer of proenzyme-based cancer therapeutics. It offers formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Their products involve or employ proenzymes, which are inactive precursors of enzymes. In the near term, they intend to target patients with limited remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, they intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening.
- Nov 2025Post IPO$100M
- Oct 2023Post IPO$40K
- Aug 2023Post IPO$120K
- Jul 2020Post IPO—
#9
Public · Bundoora, Victoria · founded 2007 · 12 employees$3Mraised▾
AdAlta develop the next generation antibody platform, the i-body, which is a human single domain antibody like molecule. The i-body platform delivers high affinity and specific biologics against a variety of therapeutic and diagnostic targets, including, cell surface, membrane spanning and complex proteins. AdAlta is growing a pipeline of i-bodies for treatment of fibrosis and cancer utilizing the i-body technology.
- Apr 2024Post IPO$3.7M
- Dec 2021Post IPO$2.7M
- Aug 2020Post IPO$4M
- Dec 2010Series A$3M
#10
Public · Melbourne, Victoria · founded 2016$2.7Mraised▾
Developer diagnostic tests for the detection of cancer. The company has developed a minimally invasive blood test for one of the most common forms of cancer. The flagship product is ColoSTAT to detect colorectal cancer.
- Jun 2024Post IPO$2.7M
#11
Public · Carlton, Victoria · founded 1994 · 6 employees$37Mraised▾
Developer of oral immunotherapy utilizing polyclonal antibody products. The product Travelan for traveler's diarrhea is a non-absorbable and safe product that has antibacterial antibodies that work on gut immune system and the gut microbiome and Protectyn that promote digestion and healthy gastrointestinal system health.
- Jul 2020Post IPO$20M
- Feb 2018Post IPO$5.1M
- Jun 2017Conventional Debt$1.5M
- Jul 2016Post IPO$5.3M
#12
Public · Melbourne, Victoria · founded 2015 · 234 employees$25Mraised▾
Developer of theranostic radiopharmaceuticals for imaging and treating cancer. It offers TX250, a Girentuximab antibody with an imaging payload (124-I or 177-Lu), targeting carbonic anhydrase IX, indicated for CCRC, and treatment with 177Lu and NSCLC.
- Nov 2020Post IPO$25M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
What Victoria researches in oncology
- University of Victoria11
- Hospital Clínico Universitario Virgen de la Victoria5
- Victoria University of Wellington4
- Cancer Council Victoria3
- Parks Victoria2
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.